30 Followers on Owler

AFFiRiS develops and manufactures peptide-based vaccines for therapeutic treatment of chronic diseases...

Read more

AFFiRiS develops and manufactures peptide-based vaccines for therapeutic treatment of chronic diseases...

Read more
AFFiRiS CEO: Oliver Siegel

CEO

Oliver Siegel

CEO Approval Rating

70/100

2004

PrivateIndependent Company

Add Industry
Add Sector
Est. Annual Revenue
<$1M
Agree?
Est. Employees
<10
Agree?
Funding
$11.3M

News

Dec 22, 2021
FirstWord PHARMA
AFFiRiS: AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
Jul 27, 2021
Endpoints News
AFFiRiS: Looking to replicate Covid-19 success in neuro, BioNTech backers bet on AC Immune and its newly-acquired Parkinson's vaccine
Jul 27, 2021
MedCity News
AFFiRiS: AC Immune picks up Phase 2-ready drug for Parkinson's in $58M deal with Affiris
May 27, 2021
StreetInsider
Press Release: AFFiRiS : AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology
Apr 27, 2021
FinanzNachrichten
AFFiRiS: DGAP-News: AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference
Sep 10, 2020
MarketScreener
AFFiRiS: AFFiRiS : announces publication in Movement Disorders Journal of positive clinical results of a Phase 1 trial in early Multiple System Atrophy
Sep 10, 2020
MarketScreener
AFFiRiS: Adamas presents new post-hoc data analysis for GOCOVRI in Parkinson's disease patients with dyskinesia at the 2020 Movement Disorder Society Virtual Congress
Jun 18, 2020
MarketScreener
AFFiRiS: AFFiRiS : The Lancet Neurology publishes positive results of AFFiRiS' Phase 1 trial with PD01A in Parkinson's disease patients
Jun 03, 2020
MarketScreener
AFFiRiS: AFFiRiS : Neurobiology of Disease publishes encouraging preclinical results of AFFiRiS' antibody mAB C6-17 to treat Huntington's disease
Apr 09, 2020
MarketScreener
AFFiRiS: World Parkinson's Day: AFFiRiS developing PD01 to treat Parkinson's disease, a major unmet medical need

AFFiRiS News

AFFiRiS Press Releases

AFFiRiS Headquarters

Karl-Farkas-Gasse 22

Vienna, Vienna1030

43-1-7981575-300

Driving Directions »

AFFiRiS Summary

ABOUT

Overview

AFFiRiS develops and manufactures peptide-based vaccines for therapeutic treatment of chronic diseases. AFFiRiS was founded in 2004. AFFiRiS's headquarters is located in Vienna, Vienna, AT 1030. AFFiRiS's CEO, Oliver Siegel, currently has an approval...

CEO

AFFiRiS's CEO, Oliver Siegel, currently has an approval rating of 70%. AFFiRiS's primary competitors are

Competitors

There are no competitors identified for AFFiRiS

Acquisitions

There have been no acquisitions found related to AFFiRiS

Investments

Recent investment data cannot be found related to AFFiRiS

Frequently Asked Questions about AFFiRiS

  1. When was AFFiRiS founded?

    AFFiRiS was founded in 2004
  2. Who is AFFiRiS's CEO?

    AFFiRiS's CEO is Oliver Siegel
  3. How much revenue does AFFiRiS generate?

    AFFiRiS generates $ < 1M in revenue
  1. How much funding does AFFiRiS have?

    AFFiRiS has historically raised $11.3M in funding
  2. Where is AFFiRiS's headquarters?

    AFFiRiS's headquarters is in Vienna Vienna, AT
  3. How many employees does AFFiRiS have?

    AFFiRiS has 0 employees

Trending Companies